Anlotinib and Benmelstobart in DTC

Official title

A Phase II Study of Anlotinib and Benmelstobart as Second-line Treatment in Locally Advanced or Metastatic Differentiated Thyroid Cancer

Overview

This study is a multicenter, open-label, phase II study to evaluate the efficacy and safety of Benmelstobart in combination with Anlotinib as a second-line treatment for locally advanced or metastatic differentiated thyroid cancer. Patients who meet the inclusion criteria and do not meet the exclusion criteria will receive Benmelstobart (1200mg, d1, q3w) in combination with Anlotinib (12mg, qd, d1-14, q3w). Treatment will continue until disease progression, voluntary withdrawal of informed consent, intolerable toxicity, or until the investigator determines that the patient no longer benefits. For locally advanced patients, if the disease converts from unresectable or borderline unresectable to resectable after treatment, surgical intervention will be performed.

Interventions

• Drug Anlotinib and Benmelstobart
  Patients will receive Benmelstobart (1200mg, d1, q3w) in combination with Anlotinib (12mg, qd, d1-14, q3w). Treatment will continue until disease progression, voluntary withdrawal of informed consent, intolerable toxicity, or until the investigator determines that the patient no longer benefits.

Primary outcome measures

• Objective Response Rate，ORR [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

• The patient voluntarily agrees to participate in this study and has signed the informed consent form;
• Age: ≥18 years, regardless of gender;
• Histologically confirmed differentiated thyroid cancer;
• Unresectable or borderline unresectable locally advanced thyroid cancer and/or metastatic thyroid adenocarcinoma;
• Failure of first-line treatment (failure to achieve partial or complete response) or disease progression after first-line treatment;
• At least one measurable lesion;
• ECOG PS: 0-2;
• Expected survival period ≥12 weeks;
• Patient agrees to undergo tumor tissue biopsy/surgery at the time of enrollment;
• Normal function of major organs;
• Willingness to use reliable contraceptive methods during the trial. Women of childbearing potential must have a negative pregnancy test (serum or urine) within 14 days prior to enrollment.
• The subject voluntarily agrees to participate in this study, signs the informed consent form, demonstrates good compliance, and cooperates with follow-up.

Exclusion criteria

• Presence of other active malignancies within the past 5 years or concurrently. Patients with cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, carcinoma in situ of the breast, etc., may be enrolled.
• Use of other antitumor therapies (including but not limited to chemotherapy, radiotherapy, etc.) within 28 days prior to the first administration of the study drug. Thyrotropin (TSH) suppressive therapy is excluded.
• Prior treatment with immune checkpoint inhibitors (including but not limited to nivolumab, pembrolizumab, toripalimab, sintilimab, etc.).
• Any severe or uncontrolled systemic disease, as determined by the investigator, including poorly controlled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg) despite medication, uncontrolled diabetes, poorly managed cardiac disease, and signs of active bleeding.
• Known history of severe allergy to any monoclonal antibody or anti-angiogenic targeted drug.
• Presence of uncontrolled infection at the time of screening.
• Pregnant or lactating women.
• Refusal to undergo tumor tissue biopsy at the time of enrollment.
• Other conditions considered by the treating physician as unsuitable for inclusion.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07193186 · ABILITY

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗